![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 01, 2022 7:16:17 PM
I'm in my 20th quarter now as a shareholder, and I get a little too impatient at times. I've got no appreciation of "puff pieces" from Wainwright and Oppenheimer, as we get. When the company announces news in regards to Lancet, at this time, when we're all expecting a peer-review of our updated results, it's extremely frustrating to find that the Lancet news was that Humanigen is featured on the cover. Was that the editor's choice, or did we pay for that? I think many of us were hoping the Lancet news was going to be more than it turned out to be.
But I have never wavered in my faith in this drug, or in Dale and Cameron. It is virtually impossible for a micro-cap biotech to do what Humanigen is on the verge of doing. But this drug, and this management team, are going to bring a blockbuster novel therapeutic to market. It will save the lives of hundreds of thousands of patients as it gets commercialized, and it will change the lives of tens of thousands of shareholders.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM